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Abstract
Recombinant adenovirus vectors have been extensively used in gene therapy clinical studies. More recently, the 
capability of inducing potent cell-mediated and humoral immunity has made these vectors equally attractive 
candidates for prophylactic or therapeutic vaccine applications. Merck and Co., Inc., developed HIV-1 vaccine 
candidates based on adenovirus serotype 5 (Ad5) vectors in which the E1 gene, a critical component for adenovirus 
replication, was replaced by the cytomegalovirus immediate/early promoter, followed by mutated versions of the HIV-
1 gag, pol or nef genes (constructs referred to as MRKAd5gag, MRKAd5pol and MRKAd5nef, respectively). Vaccine 
performance was evaluated in vitro in a novel assay that measures the level of transgene expression in non-permissive 
A549 cells. Various combinations of vectors were studied. The results indicate that the vaccine induces a dose-
dependent expression of the HIV-1 transgenes in vitro. Furthermore, the gag, pol, and nef transgenes are expressed 
differentially in A549 cells in an MOI-dependent and formulation-dependent manner, yielding an unexpected 
enhancement of protein expression in trivalent vs. monovalent formulations. Our data suggest that the presence of 
additional virus in multivalent formulations increases individual transgene expression in A549 cells, even when the 
amount of DNA encoding the gene of interest remains constant. This enhancement appears to be controlled at the 
transcriptional level and related to both the total amount of virus and the combination of transgenes present in the 
formulation.
Findings
Recent clinical trials of Adenovirus-based HIV vaccines
failed to demonstrate significant efficacy in protecting
humans from HIV-1 infection or limiting viral load,
despite strong pre-clinical immune response [1]. None-
theless, in preparation for clinical studies, significant
development took place to characterize these vaccines. In
this case, we investigated the use of non-permissive A549
cells as an in vitro model for Adenovirus type 5-based
gag, pol and nef transgene expression [2].
The ability of an Adenovirus-based vaccine to elicit a
clinical response is dependent on its ability to deliver the
appropriate transgene for expression in the vaccinee;
therefore, determining the levels of transgene expression
of a given vector can provide an appreciation of the effi-
ciency with which the vector has delivered the transgene,
offering a measure of the vaccine's relative in vitro
potency [3-5]. A549 cells were chosen specifically for
their inability to support recombinant Ad5 replication
[6], such that all transgene expression would be the result
of a single round of transgene delivery and transcription/
translation. Expression of each of the three transgenes in
this cell line was analyzed simultaneously by SDS-PAGE
and ELISA, while Reverse Transcriptase PCR (RT-qPCR)
was used to quantitate mRNA.
A549 cells were infected with monovalent formulations
of MRKAd5gag, MRKAd5pol or MRKAd5nef vectors [2]
at multiplicity of infections (MOI) ranging from 6 to
12,500 (Figure 1) [7,8]. As expected, ELISA (Figure 1A)
and RT-qPCR (Figure 1B) both demonstrate an increase
in antigen expression or transcription following increas-
ing MOIs, within the dynamic range of each assay. Over-
all, a similar trend was observed throughout the different
assays: the nef transgene appeared to be more dominantly
expressed than the gag or pol transgenes in the MOI
range of 100 to 1,000. Comparison of different gene prod-
ucts in a given assay platform must be made with caution
since each gene product signal is dependent on the affin-
ity of the detector (monoclonal antibodies for ELISA or
primers/probes for RT-qPCR). A similar observation was
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made using a direct detection approach with SDS-PAGE
followed by silver staining: analysis of infected cell lysates
revealed that the nef protein was more intense than the
pol protein (Figure 1C), suggesting that ELISA and RT-
qPCR results were not an artifact of the detectors. Nef
and pol band identities were confirmed by in-gel trypsin
digestion and MALDI-TOF peptide mapping (data not
shown). The 55-kDa gag protein could not be distin-
guished from host cell and FBS proteins.
In Phase I and Phase II clinical studies [2,9,10], the
three constructs MRKAd5gag, MRKAd5pol and
MRKAd5nef were administered simultaneously as a tri-
valent formulation. To compare each transgene's expres-
sion in the clinical trivalent  formulation with the
individual monovalent formulations, we assessed trans-
gene transcription and expression levels in both formula-
tions by ELISA and RT-qPCR (Figure 2). A549 cells were
infected with either the monovalent or the trivalent for-
mulations, normalizing the MOI for individual transgene
concentration, not for total virus concentration, therefore
allowing a direct comparison of the expression level of a
given protein from a standard amount of genetic mate-
rial. Surprisingly, the expression of gag and nef, in the lin-
e a r  r a n g e ,  a p p e a r e d  t o  b e  h i g h e r  w h e n  t h e  c e l l s  w e r e
infected with the trivalent formulation as compared with
the monovalent formulation, as seen by a shift in the tri-
valent curves to the left (Figure 2A). These results were
confirmed at the mRNA level (Figure 2B). Relative fold-
increase for gag, pol and nef transcription and expression
in trivalent relative to monovalent formulations were cal-
culated by parallel line analysis (Table 1). On average, a
1.5-fold increase was observed for gag and nef at both the
mRNA and protein levels, despite the fact that the total
concentration of the monovalent gene in each formula-
tion was constant. Pol expression by ELISA was roughly
comparable whether the cells were infected with mon-
ovalent or trivalent formulations, but pol transcription
was approximately 2-fold higher in cells infected with the
trivalent formulation as compared with the monovalent
formulation. The discrepancy observed for pol between
the ELISA and RT-qPCR data might reflect a higher sen-
sitivity of the RT-qPCR assay for this transgene. It is also
possible that the ELISA developed for pol is less robust
than the gag or nef ELISAs, presumably because the pol
primary structure used by Merck was modified from the
wild type form [1,11]. Consequently, the interaction of
this modified pol with the commercially available anti-
bodies may be suboptimal, rendering the ELISA less sen-
sitive to improvements in expression levels.
To explain this transgene expression enhancement in
the trivalent formulation we hypothesized that either the
presence of additional transgenes impacted the transcrip-
tion of each given gene or that the presence of additional
Comparison of transgene expression levels in A549 cells in-
fected with monovalent Ad5 vectors
Figure 1 Comparison of transgene expression levels in A549 cells 
infected with monovalent Ad5 vectors. A549 cells were infected 48 
hours post plant with various concentrations of monovalent Ad5 vec-
tors in α-MEM media supplemented with 10% heat-inactivated FBS 
and 5% Pen/Strep. The cells were placed at 37°C/5% CO2 for 48 hours 
and then lysed with either a sodium deoxycholate/IGEPAL buffer for 
ELISA analysis or an RNA extraction buffer (RNeasy 96 Qiagen kit). The 
cell lysates were denatured and reduced prior SDS-PAGE analysis. Gag, 
pol and nef proteins were detected by colorimetric ELISA using HRP/
TMB detection (A), gag, pol and nef mRNAs were detected by RT-qPCR 
(B). The protein profile of pol and nef proteins obtained by silver-
stained SDS-PAGE is shown in (C). The MOI was determined by the 
quantity of infectious Ad5 particles measured by quantitative PCR 
based potency assay along with total Ad5 particles as measured by a 
genome quantitation assay. The error bars represent 95% confidence 
interval.
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Comparison of transgene expression in A549 cells infected with Ad5 monovalent or trivalent formulations
Figure 2 Comparison of transgene expression in A549 cells infected with Ad5 monovalent or trivalent formulations. A549 cells were infected 
as described in figure 1 with monovalent or trivalent Ad5 vectors. Gag, pol and nef proteins were detected by colorimetric ELISA (A), gag, pol and nef 
mRNAs were detected by RT-qPCR (B). The housekeeping gene GAPDH mRNA was monitored to address cell alteration (B). The MOI used at infection 
were normalized for transgene concentration, not for total virus concentration. The error bars represent 95% confidence interval.
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viral load (3-fold higher in the trivalent formulation)
somehow facilitated the overall transgene expression.
Interestingly, at high MOI (>700 for ELISA and >1000
for RT-qPCR), more protein and mRNA were detected in
cells infected with the monovalent formulations as com-
pared with the trivalent formulations (Figure 2 and 3).
Since trivalent formulations contain three times more
virus than monovalent formulations, we evaluated the
effect of this increase in viral concentration by measuring
the steady-state transcription of a housekeeping gene,
GAPDH, across the entire dose range of the RT-qPCR
assay (Figure 2B). Cells infected with the trivalent formu-
lation showed equivalent or less GAPDH transcription at
high MOI than cells infected with the monovalent formu-
lations. The levels of GAPDH mRNA began to decrease
at MOIs ranging from approximately 700-1200, suggest-
ing that signal decrease noted at the upper limits of the
assay dose range is likely due to cell death caused by the
virus. These data indicate that although transgene
expression levels are higher in trivalent formulations, an
excessive  viral load likely compromises the cellular
machinery, possibly leading to accelerated cell death.
To investigate whether the increase of transgene
expression observed with the trivalent formulation was
due to the higher amount of virus infecting the host cells
or related to the simultaneous presence of one or more
transgenes, we infected A549 cells with monovalent for-
mulations of MRKAd5gag, MRKAd5pol or MRKAd5nef,
supplemented either with "empty vectors" (EV, Ad5 con-
structs generated in the same way as the transgene-con-
taining constructs, but missing the transgene cassette) or
with a combination of EV and another monovalent vector
to reach the equivalent number of virus particles that the
cells were exposed to with the trivalent formulation. In
this way, EV can normalize total non-replicating Ad5
virus concentration while leaving individual transgene
concentration constant.
Surprisingly, ELISA analysis from cells infected with EV
and either monovalent MRKAd5gag or MRKAd5nef
revealed that the presence of EV in a given monovalent
formulation dramatically boosted transgene expression,
even exceeding the transgene expression level of the tri-
valent formulation (Figure 3). Whereas a 50% enhance-
ment in transgene expression was observed in trivalent
relative to monovalent formulations for gag and nef
( d e t e r m i n e d  b y  p a r a l l e l  l i n e  a n a l y s i s  o n  t h e  f u l l  d o s e
response curves), the addition of EV led to 190% and
270% increases in gag and nef transgene expression,
respectively. Unlike gag and nef, no significant changes in
pol transgene expression levels could be detected in the
various infection combinations (Figure 3).
To confirm that the enhancement of transgene expres-
sion levels observed in the presence of EV was not trans-
gene-dependent and that this enhancement occurs at the
mRNA level, we compared transcription levels by RT-
qPCR of A549 cells infected by monovalent Ad5 vectors
supplemented with 2× EV or 2× of a specific Ad5 con-
struct. The results confirmed that gag and nef transcrip-
tions were maximal in conditions supplemented with EV,
especially in the MOI range of 10 to 100, and minimal in
the monovalent formulations (Figure 4). Overall
enhancement of transcription with 2× EV was 320% for
gag and almost 400% for nef, whereas the addition of 2×
of a specific Ad5 construct did not differ significantly
from the enhancement observed in the trivalent formula-
tion (determined by parallel line analysis in the MOI
ranges 10-78 of the dose response curves). These results
confirm that the maximum enhancement previously
observed derived from the presence of EV.
The data suggest that for an experimental adenovirus-
based HIV-1 vaccine, transgene expression in non-per-
missive cells in vitro can be reproducibly modulated by
the presence of additional replication-incompetent aden-
ovirus. This modulation can occur in circumstances
where another transgene-encoding adenovirus is present,
as well as with the addition of adenovirus that does not
contain the coding region for any transgene of interest.
The mere presence of additional "empty" adenovirus par-
ticles devoid of transgene appears to enhance transgene
expression. Our findings suggest these unexpected
results may be worth consideration during dose and
potency assay development for adenovirus-based thera-
peutics. Additional work is required to elucidate the
mechanism of the observed transgene expression
enhancement by the presence of additional adenoviral
vectors. The data presented suggest that the mechanisms
Table 1: Fold-increase in transgene expression when 
comparing A549 cells infected with Ad5 trivalent relative 
to Ad5 monovalent formulations.
Protein fold 
increase (95% CI)a
mRNA fold 
increase (95% CI)b
gag 1.5 (± 0.3) 1.5 (± 0.2)
pol 1.0 (± 0.1) 2.2 (± 0.2)
nef 1.7 (± 0.1) 1.6 (± 0.1)
a Average (n = 2 independent experiments) and 95% 
Confidence Interval (95% CI) of gag, pol and nef protein fold 
increases determined by parallel line analysis on the full dose 
response curves.
b Average (n = 3 independent experiments) and 95% 
Confidence Interval (95% CI) of RNA fold increases determined 
by parallel line analysis in the MOI ranges 25 -- 200 for gag and 
12-100 for nef and pol.Takahashi et al. Virology Journal 2010, 7:39
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Normalizing total virus concentration with Ad5 empty vectors and impact on transgene expression
Figure 3 Normalizing total virus concentration with Ad5 empty vectors and impact on transgene expression. A549 cells were infected as de-
scribed in figure 1. Detection of gag (A), pol (B), and nef (C) transgene expression in A549 cell lysates infected with monovalent, trivalent or multivalent 
formulations composed of monovalent vectors and empty vector to normalize total virus concentration. Fluorescence based ELISA signal is measured 
in relative fluorescence units (RFU). Similar results were observed on an independent set of experiments using OD450 detection (data not shown). The 
error bars represent 95% confidence interval (error bars for the monovalent and trivalent formulations were not available, n = 1).
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responsible for this enhancement are functioning prior to
or during the transcription of the vector transgene. We
hypothesize that the presence of additional virus results
in an increase of cellular stress signals that activate tran-
scription regulators such as MAP kinase and/or NFκB
which in turn could up-regulate the CMV promoter
activity driving transgene expression [12,13].
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Comparing the impact of Ad5 Empty Vectors vs. additional Ad5 transgenes on transgene transcription level
Figure 4 Comparing the impact of Ad5 Empty Vectors vs. additional Ad5 transgenes on transgene transcription level. RT-qPCR detection of gag 
(A), pol (B), and nef (C) transgene transcription in A549 cell lysates infected with monovalent, trivalent or multivalent formulations composed of mon-
ovalent vectors and empty vector to normalize total virus concentration. The error bars represent 95% confidence interval.
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